Israel China Biotechnology (ICB) Ltd Cash Flow Conversion Efficiency
Israel China Biotechnology (ICB) Ltd cash flow conversion efficiency. Based on the latest financial reports, Israel China Biotechnology (ICB) Ltd (ICB) has a cash flow conversion efficiency ratio of -0.415x as of June 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.06 Million ≈ $-2.84K USD) by net assets (ILA2.55 Million ≈ $6.83K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Israel China Biotechnology (ICB) Ltd stock valuation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Israel China Biotechnology (ICB) Ltd (2015–2020)
Cash flow conversion efficiency of Israel China Biotechnology (ICB) Ltd from 2015 to 2020. This chart illustrates how Israel China Biotechnology (ICB) Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ICB stock price and chart for real-time trading data and today's change.
Israel China Biotechnology (ICB) Ltd Cash Flow Conversion Ratio Explained
Israel China Biotechnology (ICB) Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Israel China Biotechnology (ICB) Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Israel China Biotechnology (ICB) Ltd ranked by their cash flow conversion efficiency. Review ICB free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shreyans Industries Limited
NSE:SHREYANIND
|
0.040x |
|
TOPBI International Holdings Ltd
TW:2929
|
-0.042x |
|
Dynamic Metals Ltd
AU:DYM
|
-0.033x |
|
Putprop Ltd
JSE:PPR
|
0.025x |
|
Austem Company Ltd
KQ:031510
|
-0.003x |
|
Octopus Robots SA
PA:MLOCT
|
N/A |
|
Frontier Nuclear and Minerals Inc.
NASDAQ:FNUC
|
N/A |
|
Naos Ex-50 Opportunities Company Ltd
AU:NAC
|
0.047x |
Annual Cash Flow Conversion Efficiency for Israel China Biotechnology (ICB) Ltd (2015–2020)
The table below shows the annual cash flow conversion efficiency of Israel China Biotechnology (ICB) Ltd from 2015 to 2020. Also see ICB total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2020-12-31 | ILA470.00K ≈ $1.26K |
ILA-4.34 Million ≈ $-11.63K |
-9.232x | -312.74% |
| 2019-12-31 | ILA1.89 Million ≈ $5.06K |
ILA-4.22 Million ≈ $-11.32K |
-2.237x | -248.93% |
| 2018-12-31 | ILA7.41 Million ≈ $19.87K |
ILA-4.75 Million ≈ $-12.74K |
-0.641x | -134.10% |
| 2017-12-31 | ILA-1.69 Million ≈ $-4.52K |
ILA-3.17 Million ≈ $-8.50K |
1.880x | +190.81% |
| 2016-12-31 | ILA1.91 Million ≈ $5.11K |
ILA-3.94 Million ≈ $-10.58K |
-2.070x | -213.83% |
| 2015-12-31 | ILA5.78 Million ≈ $15.50K |
ILA-3.81 Million ≈ $-10.23K |
-0.660x | -- |
About Israel China Biotechnology (ICB) Ltd
Silver Castle Holdings Ltd operates as a healthcare investment company. It invests in companies in the biomedical field in Israel. The company was formerly known as Israel China Biotechnology (ICB) Ltd and changed its name to Silver Castle Holdings Ltd in February 2022. Silver Castle Holdings Ltd was founded in 2000 and is based in Tel Aviv, Israel.